The paper presents Provid's novel strategy to inhibit a key pathway in multiple sclerosis that is tied to the genetic profile of patients. PV-267 specifically blocks MHC Class II DR2b (DRB1*15:01), ...
Provid to Acquire Tripos Discovery Research NORTH BRUNSWICK, N.J., Jan. 5 -- Provid Pharmaceuticals Inc. is pleased to announce that it has signed a definitive agreement to acquire Tripos Discovery ...
Provid Pharmaceuticals Inc. has announced the award of a $750,000 phase II SBIR contract by the National Cancer Institute. The NCI and Provid will collaborate on a number of oncology targets over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results